Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Brian Malloy who wrote (1176)	4/20/1999 2:34:00 PM
From: William Partmann	Read Replies (1) \| Respond to of 1580

FDA panel backs Merck's Vioxx for osteoarthritis GAITHERSBURG, Md., April 20 (Reuters) - A Food and Drug Administration panel on Tuesday voted to back Merck's (MRK - news) painkiller Vioxx to treat pain caused by osteoarthritis. The panel voted 8-0 to recommend approval for Vioxx for osteoarthritis, the wear-and-tear joint pain that afflicts about 21 million Americans. The panel was still considering whether to support Vioxx for acute pain such as menstrual cramps and post-surgical pain.